123i-mip-1072

Small moleculeexperimentalImaging agent

Clinical trial activity

2 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2008 (NCT00712829)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
123-iodine

Oral

No

Parenteral

No

Topical

No

Also known as

  • 123i-mip-1072
  • 123i-mip-1072

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00992745Phase 1Oct 1, 2009Cornell University, Duke University, Molecular Insight Pharmaceuticals, Pacific Coast Imaging, University of California, San Francisco, University of Maryland, Vanguard Urologic Research Foundation, West Coast Radiology Centerse
NCT00712829Phase 1May 1, 2008Molecular Insight Pharmaceuticals
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Molecular Insight PharmaceuticalsFor profit2212008
Cornell UniversityAcademic/Hospital1012009
Duke UniversityAcademic/Hospital1012009
Pacific Coast ImagingAcademic/Hospital1012009
University of California, San FranciscoAcademic/Hospital1012009
University of MarylandAcademic/Hospital1012009
Vanguard Urologic Research FoundationAcademic/Hospital1012009
West Coast Radiology CenterseAcademic/Hospital1012009
8 organizations
Page 1 / 1